CCA
ICPT

Column Capital Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Column Capital Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-300
Closed -$7K – 742
2021
Q1 		$7K Hold
300
– – ﹤0.01% 512
2020
Q4 		$7K Hold
300
– – ﹤0.01% 506
2020
Q3 		$12K Hold
300
– – ﹤0.01% 421
2020
Q2 		$14K Hold
300
– – ﹤0.01% 433
2020
Q1 		$19K Sell
300
-37
-11% -$3.33K 0.01% 321
2019
Q4 		$41K Buy
+337
New +$30.2K 0.02% 273

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Column Capital Advisors's ICPT Position: Q2 2021 in Review

Column Capital Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2021, closing a stake of 300 shares — an estimated $7K sold.

Column Capital Advisors first reported a position in ICPT in Q4 2019 and held it in 6 quarters. The position peaked at $41K in Q4 2019. 129 funds tracked by Wall St. Rank hold ICPT as of Q2 2021.

  • Column Capital Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Column Capital Advisors sold 300 Intercept Pharmaceuticals, Inc. shares in Q2 2021, an estimated $7K.
  • Column Capital Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2019 and held it in 6 quarters.
  • Column Capital Advisors's Intercept Pharmaceuticals, Inc. position peaked at $41K in Q4 2019.
  • 129 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2021.

Based on Column Capital Advisors's 13F filing for Q2 2021, filed 5 Aug 2021.